SAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF)

Treatment of NVAF: The most common adverse reactions (≥ 5%) are bleeding and anemia.
Treatment of DVT and PE: The most common adverse reactions (≥ 1%) are bleeding, rash, abnormal liver function tests and anemia

• Anticoagulants: Avoid concomitant use
• Rifampin: Avoid concomitant use

• Bleeding: Serious and potentially fatal bleeding. Promptly evaluate signs and symptoms of blood loss
• Mechanical heart valves or moderate to severe mitral stenosis: Use is not recommended